Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.41 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.41 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255420 | 0.99 | MAPT (0.48) | MAPTSMN1; SMN2RAB9AHTTALDH1A1 | |
| Bromide SCHEMBL3042040 | 0.85 | ALDH1A1 (0.45) | MAPTSMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL5015881 | 0.84 | CA12 (0.45) | MAPTSMN1; SMN2RAB9AALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL7759140 | 0.82 | RAB9A (0.46) | MAPTSMN1; SMN2RAB9AALDH1A1GFER | |
| Bromide SCHEMBL3851561 | 0.77 | MAPT (0.50) | MAPTSMN1; SMN2RAB9AHTTALDH1A1 | |
| SCHEMBL6938200 | 0.75 | ALDH1A1 (0.49) | MAPTSMN1; SMN2RAB9AHTTALDH1A1 | |
| SCHEMBL11545365 | 0.73 | LMNA (0.38) | MAPTSMN1; SMN2HTTALDH1A1LMNA | |
| Bromide SCHEMBL2946957 | 0.72 | MAPT (0.45) | MAPTSMN1; SMN2RAB9AHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL2150060 | 0.72 | LMNA (0.37) | MAPTSMN1; SMN2HTTALDH1A1LMNA | |
| Bromide SCHEMBL2945063 | 0.71 | ALDH1A1 (0.45) | MAPTSMN1; SMN2RAB9AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7622117-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1098647-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING TISSUE ISCHEMIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003711-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING TISSUE ISCHEMIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-01-27 | — | — | WO | disclosed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | disclosed |
| EP-0808163-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5656261-A | USING A THIAZOLIUM COMPOUND | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996022095-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | MAPT 677/4885SMN1; SMN2 2850/4885RAB9A 3851/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | MAPT 3453/4885SMN1; SMN2 3746/4885RAB9A 3894/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | MAPT 3453/4885SMN1; SMN2 3746/4885RAB9A 3894/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | MAPT 2715/4885SMN1; SMN2 3654/4885RAB9A 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.